WASHINGTON — Before the coronavirus pandemic became Congress’ sole focus, late May was widely viewed as a final 2020 deadline for lawmakers to take action on key health policy issues, including legislation to lower the price of prescription drugs.

But with the Covid-19 crisis dominating every aspect of American politics, such legislation will have to wait. A recent $2 trillion relief package that lawmakers passed on Friday could mean drug pricing advocates might be waiting a long while — likely until November, weeks after Election Day.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This is indeed a very sensible, logical, and welcome news for the drug industry since the $2 trillion package does not include any subsidy or loan or any break for the industry compare to airline, travel, etc.

    In fact I hope the industry would by November have come up with an effective treatment and also would have made significant progress towards a coronavirus vaccine and broadcast pervasively and ubiquitously as the result of continuous innovation. Hopefully any drug pricing legislation would thus be postponed for years and not merely months! Of occurs the only caveat would be the treatment and the vaccine must be priced reasonably!

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy